-transparent.png){kind=logo}
Adriamycin (doxorubicin), a potent antitumor drug in clinical use, interacts with nucleic acids and cell membranes, but the molecular basis for its antitumor activity is unknown. Similar to a number of intercalative antitumor drugs and nonintercalative epipodophyllotoxins (VP-16 and VM-26), adriamycin has been shown to induce single- and double-strand breaks in DNA. These strand breaks are unusual because a covalently bound protein appears to be associated with each broken phosphodiester bond. In studies in vitro, mammalian DNA topoisomerase II mediates DNA damage by adriamycin and other related antitumor drugs.
Related Publications
K M Tewey, and
T C Rowe, and
L Yang, and
B D Halligan, and
L F Liu
April 1986,
Cancer research,
K M Tewey, and
T C Rowe, and
L Yang, and
B D Halligan, and
L F Liu
March 1997,
The Journal of biological chemistry,
K M Tewey, and
T C Rowe, and
L Yang, and
B D Halligan, and
L F Liu
April 2003,
Proceedings of the National Academy of Sciences of the United States of America,
K M Tewey, and
T C Rowe, and
L Yang, and
B D Halligan, and
L F Liu
January 2022,
Frontiers in molecular biosciences,
K M Tewey, and
T C Rowe, and
L Yang, and
B D Halligan, and
L F Liu
January 2000,
Annals of the New York Academy of Sciences,
K M Tewey, and
T C Rowe, and
L Yang, and
B D Halligan, and
L F Liu
July 1999,
Nucleic acids research,
K M Tewey, and
T C Rowe, and
L Yang, and
B D Halligan, and
L F Liu
May 1992,
Cancer research,
K M Tewey, and
T C Rowe, and
L Yang, and
B D Halligan, and
L F Liu
January 2005,
Nucleic acids research,
K M Tewey, and
T C Rowe, and
L Yang, and
B D Halligan, and
L F Liu
December 1994,
Mutation research,
K M Tewey, and
T C Rowe, and
L Yang, and
B D Halligan, and
L F Liu
March 1996,
The Journal of biological chemistry,
